ArriVent BioPharma, Inc.(AVBP)
$13.01-0.06 (-0.46%)
AVBP
ArriVent BioPharma, Inc. stock forecast
$13.01
At close:-0.06 (-0.46%)
Want to see AVBP full AI Analyst Report?
ArriVent BioPharma, Inc. (AVBP) Stock Forecast & Price Target
101 Followers
AVBP Analyst Ratings
Strong Buy
11Buy0Hold0Sell
Based on 11 analysts giving stock ratings to ArriVent BioPharma, Inc. in the past 3 months
AVBP Stock 12 Month Forecast
Average Price Target
$24.20▲(86.01% Upside)Based on 11 Wall Street analysts offering 12 month price targets for ArriVent BioPharma, Inc. in the last 3 months. The average price target is $24.20 with a high forecast of $30.00 and a low forecast of $15.00. The average price target represents a 86.01% change from the last price of $13.01.
Past 12 Months12 Month ForecastJan2026Oct2026
High$30.00
Average$24.20
Low$15.00
Highest Price TargetHighest$30.00Average Price Target$24.20Lowest Price TargetLowest$15.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Yigal Nochomovitz | Citi | $20→$23 | buy | 76.79%Upside | Reiterated | 11/11/26 | ||
| Robert Burns | H.C. Wainwright | $27 | buy | 107.53%Upside | Reiterated | 11/10/26 | ||
| Supawat Thongthip | Truist Financial | $21→$24 | buy | 84.47%Upside | Reiterated | 11/10/26 | ||
| Jeff Jones | Oppenheimer | $25 | buy | 92.16%Upside | Reiterated | 11/10/26 | ||
| Boris Peaker | JonesTrading | $22 | buy | 69.10%Upside | Reiterated | 11/10/26 | ||
| Jeet Mukherjee | BTIG | $29 | buy | 122.91%Upside | Reiterated | 11/09/26 | ||
| Michael Schmidt | Guggenheim | $18→$30 | buy | 130.59%Upside | Reiterated | 10/26/26 | ||
| Kaveri Pohlman | Clear Street | ― | buy | ― | Reiterated | 10/25/26 | ||
| Mayank Mamtani | B. Riley Securities | $45→$29 | buy | 122.91%Upside | Reiterated | 10/20/26 | ||
| Sam Slutsky | LifeSci Capital | $43→$15 | buy | 15.30%Upside | Reiterated | 10/06/26 | ||
| Kelly Shi | Jefferies | $45→$18 | buy | 38.36%Upside | Reiterated | 10/06/26 | ||
| Asthika Goonewardene | Leerink Partners | $45 | buy | 245.89%Upside | Reiterated | 08/13/26 | ||
| Li Watsek | Cantor Fitzgerald | ― | buy | ― | Initiated | 12/22/25 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Yigal NochomovitzCiti | BuyReiterated$20→$23 | 11/11/26 | 76.79%Upside | ||
| Robert BurnsH.C. Wainwright | BuyReiterated$27 | 11/10/26 | 107.53%Upside | ||
| Supawat ThongthipTruist Financial | BuyReiterated$21→$24 | 11/10/26 | 84.47%Upside | ||
| Jeff JonesOppenheimer | BuyReiterated$25 | 11/10/26 | 92.16%Upside | ||
| Boris PeakerJonesTrading | BuyReiterated$22 | 11/10/26 | 69.10%Upside | ||
| Jeet MukherjeeBTIG | BuyReiterated$29 | 11/09/26 | 122.91%Upside | ||
| Michael SchmidtGuggenheim | BuyReiterated$18→$30 | 10/26/26 | 130.59%Upside | ||
| Kaveri PohlmanClear Street | BuyReiterated | 10/25/26 | ― | ||
| Mayank MamtaniB. Riley Securities | BuyReiterated$45→$29 | 10/20/26 | 122.91%Upside | ||
| Sam SlutskyLifeSci Capital | BuyReiterated$43→$15 | 10/06/26 | 15.30%Upside | ||
| Kelly ShiJefferies | BuyReiterated$45→$18 | 10/06/26 | 38.36%Upside | ||
| Asthika GoonewardeneLeerink Partners | BuyReiterated$45 | 08/13/26 | 245.89%Upside | ||
| Li WatsekCantor Fitzgerald | BuyInitiated | 12/22/25 | ― |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering ArriVent BioPharma, Inc.
3 Months
Success Rate11/18 ratings generated profit
61%
Average Return
+4.98%
Copying Robert Burns's trades and holding each position for 3 Months would result in 61.11% of your transactions generating a profit, with an average return of +4.98% per trade.
1 Year
Success Rate8/18 ratings generated profit
44%
Average Return
-0.09%
Copying Robert Burns's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -0.09% per trade.
2 Years
Success Rate3/9 ratings generated profit
33%
Average Return
-19.23%
Copying Jeff Jones's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -19.23% per trade.
AVBP Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 6 | 14 | 16 |
| Buy | 14 | 12 | 10 | 16 | 12 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 20 | 17 | 16 | 30 | 28 |
In the current month, AVBP has received 28 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AVBP average Analyst price target in the past 3 months is 24.20.
AVBP Financial Forecast
High$-0.90
Consensus$-1.00
Low$-1.44
AVBP Earnings Forecast
Next quarter’s earnings estimate for AVBP is -$1.00 with a range of -$1.44 to -$0.90. The previous quarter’s EPS was -$0.81. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$0.00
Consensus$0.00
Low$0.00
AVBP Sales Forecast
Next quarter’s sales forecast for AVBP is $0 with a range of $0 to $0. The previous quarter’s sales results were $5.00M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
AVBP Stock Forecast FAQ
What is AVBP’s average 12-month price target, according to analysts?
Based on analyst ratings, ArriVent BioPharma, Inc.’s 12-month average price target is $24.20.
What is AVBP’s upside potential, based on the analysts’ average price target?
ArriVent BioPharma, Inc. has 86.01% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AVBP a Buy, Sell or Hold?
ArriVent BioPharma, Inc. has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
What is ArriVent BioPharma, Inc.’s price target?
The average price target for ArriVent BioPharma, Inc. is $24.20. This is based on 11 12-month price targets, issued in the past 3 months. The highest analyst price target is $30.00, the lowest forecast is $15.00. The average price target represents a 86.01% increase from the current price of $13.01.
What do analysts say about ArriVent BioPharma, Inc.?
ArriVent BioPharma, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Street analysts.
How can I buy shares of AVBP?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
